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Introduction
Systematic reviews and meta-analyses provide an objective
and reliable way of summarising trial results, and can
inform both clinical practice and the design, conduct and
reporting of trials. However, those based on aggregate data
are sometimes limited by the availability of such data,
while those based on more comprehensive individual par-
ticipant data (IPD) can provide more detailed and reliable
results. Also, IPD meta-analyses provide a resource for
secondary hypothesis testing, which can produce further
clinical insight, and rely on close collaboration with trials
organisations worldwide. Thus, IPD meta-analyses have
the potential to better inform new and on-going trials.
Methods
Initially, we sought examples of IPD meta-analyses that
have directly influenced the design and conduct of trials,
via a workshop of international experts in the field, and
subsequently, through this subgroup of workshop atten-
dees. We also considered additional ways that IPD
meta-analysis could impact on trials.
Results
In terms of trial design, IPD meta-analyses results have
informed the choice of comparators; definition of trial
populations; sample size calculations and effect sizes to
target. They have also been the catalyst for international
collaboration on new trials; justified both continuing
and stopping trial recruitment, and informed stratifica-
tion of trial analyses. They have the potential to inform
other aspects, such as the choice and definition of out-
comes. We illustrate these impacts in a range of health
care areas including cancer, cardiovascular disease,
stroke and neonatal care.
Conclusions
IPD meta-analyses have impacted on trials in various
ways, but might be utilised more widely.
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